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Abstract: Neurotrophic factors are a group of proteins that act as paracrine and autocrine growth factors. They are involved in the 
regulation of morphogenesis and development of several tissues. The present study aims to evaluate, for the first time, the expression 
of Neurotrophin-3 in the human placenta during normal pregnancy and in preeclampsia and chorioamnionitis. Neurotrophin-3 mRNA, 
assessed by RT-PCR analysis in six term placentas, were observed in all the specimens examined. Neurotrophin-3 protein expression 
and tissue distribution was evaluated by immunohistochemistry in placenta samples from uncomplicated first trimester (n = 5) and term 
(n = 5) pregnancies as well as in specimens from preeclampsia (n = 5) and chorioamnionitis (n = 5). In first trimester specimens, strong 
immunoreactivity was present in villous stromal cells, in the cyto- and syncytiotrophoblast, in decidua cells and in endometrial glands. 
Third trimester specimens showed prominent immunostaining in cyto- and syncytiotrophoblast cells, in decidua cells and in the amniotic 
membranes. Villous stromal cells were weakly stained. Similar protein localization was observed in placentas with preeclampsia and 
chorioamnionitis. In the latter, however, positive villous stromal cells increased in number and in staining intensity when compared 
with controls and preeclampsia (p  0.001). The roles of Neurotrophin-3 in pregnancy are presently unknown. A regulatory function on 
placenta and foetal brain development and maternal inflammatory response may be hypothesized.
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Introduction
Neurotrophins (NT) are a group of functionally and 
structurally related polypeptides that share about 
50% amino acid sequence and act as paracrine and 
autocrine growth factors. One gene family encodes 
the neurotrophins, and amino acids are clustered in 
conserved regions alternated by variable regions; 
this  combination  defines  the  biological  functions 
of these proteins.1 Neurotrophic factors comprise 
a  family  of  proteins  including  nerve  growth 
factor  (NGF),  brain-derived  neurotrophic  factor 
(BDNF), neurotrophin 3 (NT-3) and neurotrophin 
4  (NT-4).  These  proteins  control  generation, 
survival,  differentiation  and  death  of  neurons 
in  the  peripheral  and  central  nervous  system 
in  embryonic  and  postnatal  stages,  as  well  as 
neuronal  maintenance  later  in  life.2,3  Outside  the 
nervous system, NTs can regulate morphogenesis, 
proliferation  and  apoptosis4–6  and  seem  to  be 
involved  in  the  development  of  organs  such  as 
kidney, muscles and heart.7,8
The  NT-3  gene  is  localized  on  chromosome 
129  and  it  is  considered  the  neurotrophin  ancestor 
gene.9,10 NT-3 presents a structure similar to that of 
NGF and BDNF,5,11,12 but unlike them, its levels in 
the central nervous system are higher during foetal 
development than in adult life.6,11 In particular, NT-3 
is thought to be implicated in the development and 
maturation  of  sympathetic  neurons.  In  migratory 
neural  crest  cells,  the  reported  mitotic  effect  of 
NT-3  indicates  an  involvement  in  gangliogenesis 
and highlights an autocrine and/or paracrine action 
required for proliferation, differentiation and survival 
of sympathetic neuroblasts.13
We have previously demonstrated the expression 
of NGF mRNA and peptide in human trophoblast, 
decidua  and  fetal  membranes  in  first  and  third 
trimester of pregnancy, hypothesizing a role for this 
neurotrophic  factor  in  the  regulation  of  placental 
development and in fetal growth.14 The aim of the 
present  study  is  to  examine  the  expression  of  a 
different  neurotrophic  factor,  NT-3,  in  the  human 
placenta.  In  the  view  of  the  numerous  different 
actions of neurotrophins, we have also investigated 
the  expression  of  NT3  in  placental  samples  from 
women with chorioamnionitis and preeclampsia, the 
most frequent pathologies of the third trimester of 
pregnancy.
Materials and Methods
Tissue collection
Specimens  of  human  placenta  and  decidua  were 
obtained from five pregnancies electively terminated 
between  8  and  12  weeks  of  gestation,  and  from 
five  pregnancies  at  term  (gestational  age  between 
38  and  40 weeks)  after  elective  cesarean  section. 
Gestational age was calculated on the basis of the 
last menstrual period and confirmed by ultrasound 
evaluation.  Specimens  were  also  obtained  from 
preeclamptic women (n = 5) (low or mild form of 
the disease, elective cesarean section between 37 and 
39 weeks) and from patients with chorioamnionitis 
(n = 5) (cesarean section between 37 and 40 weeks). 
The diagnosis of preeclampsia was made on clinical 
evidence  of  maternal  hypertension  and  increased 
urinary  proteins.15  The  diagnosis  of  subclinical, 
histologic chorioamnionitis was made at histological 
examination by the presence of acute inflammatory 
infiltrate in the amniotic membranes and umbilical 
cords.16  Three  patients  presented  with  antecedent 
PPROM.  The  study  was  approved  by  the  local 
ethics committee (University of Siena) and informed 
consent was obtained from all women. The specimens 
were separated in different aliquots: i) immediately 
submerged in a RNA stabilization reagent (RNAlater; 
QIAGEN,  Valencia,  CA,  USA)  for  subsequent 
extraction  of  total  RNA  and  reverse  transcriptase-
polymerase chain reaction (RT-PCR) and; ii) fixed by 
immersion in 10% buffered formalin for the evaluation 
of  peptide  localization  by  immunohistochemistry. 
Placenta  sampling  for  histology  included  multiple 
full-thickness  placental  blocks  (10  ×  10 mm), 
membranes,  and  sections  of  the  umbilical  cord  at 
three  different  levels.  For  each  specimen,  a  block 
representing  both  the  maternal  decidua  and  the 
amnion layer was selected for IHC.
rnA extraction and rT-PCr
Total RNA was extracted from normal placenta at 
term (n = 6) using the SV total RNA extraction kit 
(Promega Corporation Madison, WI, USA) following 
the procedure indicated by the manufacturer. RNA 
integrity was tested by agarose gel electrophoresis in 
the presence of 2.2 M formaldehyde. NT-3 mRNA was 
detected  by  reverse  transcriptase-polymerase  chain 
reaction (RT-PCR). One µg of total RNA was diluted 
in a reaction buffer volume of 20 µL. The mixture expression of placental neurotrophin-3 (nT-3)
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was incubated at 42 °C for 15 minutes, 99 °C for 
5 minutes and 5 °C for 5 minutes in a programmable 
thermal  cycler  (Bio-Rad,  Hercules,  CA,  USA). 
For  each  RNA  specimen,  a  negative  control  was 
prepared  by  omitting  the  reverse  transcriptase. 
Gene-specific  primers  used  for  PCR  were  chosen 
according to the published sequence of the human 
NT-3  and  GAPDH  mRNA  (GenBank  NM002527 
and  NM  002046).  The  NT-3  forward  primer  was 
5’-TGGCATCCAAGGTAACAACA-3’,  the  reverse 
primer  was  5’-CTCTGTTGTCGCAGCAGTTC-3’, 
and  expected  size  of  the  amplified  fragment 
was  249  bp.  The  GAPDH  forward  primer  was 
5’-GAAGGTGAAGGTCGGAGTC-3’,  the  reverse 
primer  was  5’-GAAGATGGTGATGGGATTTC-3’ 
and the expected size of the amplified fragment was 
226 bp. For RT-PCR, 2 µL of RT reaction product 
was added to a mix containing 5X reaction buffer 
[300 mM  Tris-HCl  (pH  8.5),  75 mM  (NH4)2SO4, 
7.5 mM MgCl2], dNTP mixture (final concentration 
0.25 mM), 1.0 U cloned Thermus aquaticus DNA 
polymerase  (Invitrogen  Corporation  Carlsbad,  CA, 
USA), and NT-3 primers (final concentration 0.4 µL) 
in a volume of 50 µL. PCR was carried out for 1 minute 
at 94 °C, 1 minute at 60 °C and 1 minute at 72 °C for 
35 cycles followed by a final 10 minutes at 72 °C. For 
each specimen, a blank was prepared using 2 µL of 
the corresponding RT blank. One-fifth of each PCR 
solution was fractioned by electrophoresis in a 1.8% 
agarose gel. Gels were stained with ethidium bromide, 
destained and photographed.
immunohistochemistry
To  evaluate  the  localization  of  NT-3, 
immunohistochemistry was carried out on 5 µm thick 
sections  obtained  from  paraffin-embedded  samples, 
mounted  on  electrostatically  charged  slides  and 
dried  overnight  at  37  °C.  Sections  were  de-waxed, 
re-hydrated and washed in Tris-buffered saline [TBS: 
20 mM Tris-HCl, 150 mM NaCl (pH 7.6)]. Tissues were 
rinsed in 3% hydrogen peroxide to block endogenous 
peroxidase and heated in a microwave oven 3 times for 
5 minutes at 750 W in EDTA solution (0.05 M pH 8). 
Slides were incubated 1 hour at room temperature with 
primary  antibody.  NT-3  polyclonal  goat  antibody 
was obtained from R&D systems (Minneapolis, MN, 
USA) and used at the dilution of 1:300. The reaction 
was  developed  by  the  streptavidin-biotin  technique 
(Universal DakoCytomation LSAB® + Kit, Peroxidase; 
Thermo Fisher Scientific, Fremont, CA, USA) using 
diaminobenzidine  tetrahydrochloride  as  chromogen 
(DakoCytomation  Liquid  DAB  substrate  Chromogen 
System).  Harris  hematoxylin  was  used  for  nuclear 
counterstaining. A positive reaction was characterized 
by  the  presence  of  granular  brown  staining  in  the 
cytoplasm.
The intensity of immunostaining was graduated in 
a semiquantitative manner. In particular, 0 indicated 
absence of stain, + indicated weak staining in few 
cells (below 10%), ++ indicated positivity in several 
cells  (between  10  and  80%),  +++  indicates  strong 
positivity in most of the cells (over 80%).
statistics
The  intensity  of  staining  in  control  versus 
chorioamnionitis or preeclampsia cases was compared 
using the chi-square test, with significance set at a 
probability value of p  0.05.
Results
rT-PCr
The expression of NT-3 in human placenta was first 
evaluated by RT-PCR analysis. One µg of total RNA 
extracted  from  term  placenta  (n  =  6)  was  reverse 
transcribed  and  amplified  in  the  presence  of  NT-3 
primers. An intense band, corresponding in size to the 
NT-3 product, was obtained from the cDNA of all the 
specimens examined (Fig. 1). The identity of the NT-3 
cDNA was confirmed by direct DNA sequencing. Lack 
of PCR products was observed in negative controls 
obtained by omitting the reverse transcriptase (Fig. 1).
immunohistochemistry
Immunostaining  of  paraffin-embedded  sections  of 
human  placenta  revealed  that  NT-3  was  strongly 
expressed  throughout  pregnancy.  In  first  trimester 
placenta,  strong  and  consistent  immunopositivity 
was  evident  in  villous  stromal  cells  and  in  the 
cyto- and syncytiotrophoblast. Fetal vessels were also 
intensively stained (Fig. 2A and 2B). On the maternal 
side,  positivity  was  observed  in  the  decidualized 
stromal cells and in the epithelial cells of endometrial 
glands. Walls of maternal vessels were also intensively 
stained (Fig. 2C and 2D).
In  third  trimester  specimens  from  physiological 
pregnancies, maternal decidua cells showed an intense Casciaro et al
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Figure 1. reverse transcriptase—PCr analysis of nT-3 mrnA levels (A) in placental tissues. One µg of total rnA of six placenta specimens (lanes 1–6) 
was reverse transcribed and amplified in the presence of NT-3 (A) and Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (B) primers. For each 
specimen a negative control, prepared by omitting the reverse transcriptase, was amplified and loaded onto the gel (A: unmarked lanes). Thirty cycles 
were run for each PCr. The size of the molecular weight makers (lanes M; bp) is indicated.
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Figure 2. Immunohistochemical analysis of NT-3 expression in first trimester samples. A (100X, original magnification) immature villi (insert, negative 
control); arrowhead indicates a fetal vessel. B (400X), immature villi. C (100X) and D (400X), decidua; arrows indicate endometrial glands; arrowheads 
show maternal vessels.expression of placental neurotrophin-3 (nT-3)
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positivity.  Extravillous  trophoblast  lining  maternal 
decidual vessels also expressed NT-3 (Fig. 3A). Fetal 
membranes presented immunopositivity in amniotic 
cells, in the stroma cells of the chorionic layer, in the 
extravillous trophoblast and in the decidua capsularis 
(Fig.  3B).  Normal  term  placenta  presented  strong 
protein  expression  in  villous  cytotrophoblast  and 
syncytiotrophoblast. However, unlike first trimester 
placenta, only a minority of villous stromal cells were 
stained.  Fetal  vessel  walls  were  positively  stained 
(Fig. 3C and 3D).
In chorioamnionitis, the number and the intensity 
of staining of villous stromal cells increased compared 
to normal control tissues (Fig. 4B). Statistical analysis 
confirmed  an  increased  expression  of  NT3  in  the 
stroma of the terminal villi, either when comparing 
chorioamnionitis  to  normal  pregnancy  (Table) 
or  to  preeclampsia  (data  not  shown)  (chi-square 
test, p  0.001, DF = 3). Cyto- and syncytiotrophoblast, 
fetal and maternal vessel cells and decidua showed a 
staining intensity comparable to that of control tissues 
(Fig. 4A and 4B).
No staining differences were observed in specimens 
with  preeclampsia  compared  to  control  tissues. 
Immunopositivity  was  localized  in  the  cyto-  and 
syncytiotrophoblast cells and in the endothelial cells 
of fetal vessels. In the villous stroma only few cells 
were stained. Decidua was also stained together with 
some sporadic inflammatory cells (Fig. 4C and 4D).
Discussion
The present study demonstrated, for the first time, 
the presence of NT-3 transcript and protein in the 
physiological and pathological placenta throughout 
pregnancy. The exact role and functions of placental 
neurotrophins  are  presently  unknown.  Previous 
studies, however, have established that these proteins 
play  a  key-role  in  the  developing  central  and 
peripheral nervous system and that they might also 
modulate  angiogenesis  and  affect  the  development 
of  several  organs  and  tissues.10  These  data  might 
therefore  suggest  a  role  for  neurotrophins  in  the 
developing placenta and growing foetus. Indeed, as 
described  by  Malamitsi-Purcher  et al17  high  levels 
of circulating neurotrophins are found in both foetal 
and  maternal  plasma. These  authors  proposed  that 
circulating levels of neurotrophins mirror the central 
nervous system levels, since these proteins can easily 
cross the immature blood-brain barrier. Yet, maternal 
plasma levels of neurotrophins are much higher than 
fetal/neonatal levels.18 The results of the present study, 
showing NT-3 expression by decidua and trophoblast 
A B
C D
Figure 3. immunohistochemical analysis of nT-3 expression in normal third trimester samples. A (200X, original magnification) decidua (arrow indicates a 
maternal vessel lined by extravillous trophoblast). B (200X), amniotic membranes (insert, negative control). c (100X) and D (400X) mature villi (D: arrow 
indicates a maternal macrophage).Casciaro et al
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cells lining the maternal blood spaces in the placenta, 
indicate these cells as a likely source of circulating 
NT-3 in the maternal plasma.
Neurotrophin signal transduction cascade is initiated 
by the interaction with specific high affinity receptors, 
the tropomyosin-related tyrosine kinase receptors A-C 
(TrkA for NGF, TrkB for BDNF and NT4, and TrkC 
for NT3) and with the low affinity receptor p75NTR.19–23 
These receptors are expressed in neurons of central and 
peripheral nervous system, although the Trk and the 
p75NTR receptors are also found in non-neuronal cells 
including immune cells, smooth muscle and epithelial 
cells and fibroblasts.7 Immune cells, including B and 
T lymphocytes and monocytes,24 can synthesize and 
secrete  a  variety  of  neurotrophins,  including  NGF, 
BDNF,  NT-3  and  NT-4  and  are  found  to  express 
neurotrophin receptors such as TrkA, TrkB and TrkC. 
These are believed to be activated in an autocrine and 
paracrine fashion.25 Moreover, it has been observed 
that antigen activation increases neurotrophin secretion 
by  lymphocytes.26  Thus,  immune  cells  express 
neurotrophin receptors and can be targeted through an 
autocrine and/or paracrine mechanism.
An  additional  observation  of  the  present  study 
is  the  increased  NT-3  expression  in  placental  fetal 
tissues during acute inflammation. We speculate that 
over expression of NT-3 may influence and regulate 
inflammatory cell migration to the placenta and fetal 
membranes, as has been described in different contests.27 
Indeed,  TrkC,  the  high  affinity  receptor  for  NT-3, 
is  expressed  by  human  monocytes,  T-lymphocytes 
and  mast  cells.28–31  Through  this  pathway,  NT-3 
could  modulate  the  production  of  granulocytes 
chemoattractant, such as interleukin-1β, tumor necrosis 
factor α, and colony stimulating factors. Furthermore, 
augmented placental production of NT-3 might also 
increase the circulating levels of the protein in the fetal 
plasma. Thus, placenta neurotrophin could play a role 
in protecting the developing fetal brain by damages 
induced directly or indirectly by microorganisms and 
by the placental inflammatory reaction.
Table  1.  immunostaining  of  nT-3  in  physiological 
pregnancy and chorioamnionitis.
0 + ++ +++
Physiological pregnancy n = 0 n = 4 n = 1 n = 0
Chorioamnionitis n = 0 n = 0 n = 1 n = 4
Five  specimens  of  physiological  pregnancy  and  five  chorioamnionitis 
were examined. The following scoring system was used: 0, absence of 
stain; +, weak staining in few cells (below 10%); ++, positivity in several 
cells (between 10 and 80%); +++, strong positivity in most of the cells 
(over 80%).
A B
C D
Figure 4. Immunohistochemical analysis of NT-3 expression in chorioamnionitis (A, 100X and B, 400X) and preeclampsia (C and D, 200X). In B all the 
cells present in the villous stroma are positively immunostained.expression of placental neurotrophin-3 (nT-3)
Clinical Medicine: Pathology 2009:2   15
publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
In  conclusion,  the  present  study  showed  that 
placenta  and  fetal  membranes  produce  NT-3. 
Neurotrophin  expression  may  affect  placenta  and 
foetal brain development and maternal inflammatory 
response.  Additional  studies  will  help  to  better 
clarify the exact role that these proteins play in the 
physiopathology of human pregnancy.
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